MedTrace Logo

First-In-Human Study of KHN922 for Injection

NCT07514975 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2026-04-09

No results posted yet for this study

Summary

A Phase 1/2 Study of KHN922 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumors Cancer

Interventions

DRUG

KHN922 for injection

KHN922 for injection is a dual-payload Antibody Drug Conjugate (ADC) targeting HER3 antigens，intravenous (IV) administration every three weeks (D1) .

Sponsors & Collaborators

  • Chengdu Kanghong Biotech Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Qing Zhou · Guangdong Provincial People's Hospital

  • Yan Zhang · Shandong Cancer Hospital&Institute

  • Xin Wang · Shanxi Province Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-30
Primary Completion
2028-04-30
Completion
2029-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07514975 on ClinicalTrials.gov